IL6 and neoplasm: Tipifarnib significantly reduced tumor nodule formation and exhibited anti-tumor and anti-inflammatory effects in a MASH-related HCC mouse model challenged with DEN and a high-fat diet (HFD), primarily by decreasing serum IL-6 (Yamada et al., 2023).